Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 1;140(5):883-897.
doi: 10.1097/AOG.0000000000004967. Epub 2022 Oct 5.

Long-Acting Reversible Contraception

Courtney C Baker  1 , Mitchell D Creinin
Affiliations
Free article
Review

Long-Acting Reversible Contraception

Courtney C Baker et al. Obstet Gynecol. .
Free article

Abstract

Long-acting reversible contraceptive (LARC) methods are effective options for pregnancy prevention. Currently available products in the United States include an etonogestrel implant, a copper intrauterine device (IUD), and several levonorgestrel IUDs. With increasing prevalence and duration of use, our understanding of efficacy, risks, and benefits has evolved. In addition to a brief discussion on nomenclature and LARC use within a framework of bodily autonomy and reproductive justice, this review covers clinical challenges with placement and removal, evidence-based duration of use, and how to mitigate side effects. Although all obstetrician-gynecologists as well as primary care clinicians can safely provide LARCs, complex family planning specialists are an expert referral source for challenging cases and evidence-based care as contraceptive technology continues to develop.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure Mitchell D. Creinin has received speaking honoraria from Gedeon Richter and Mayne, serves on an Advisory Boards for Evofem, Fuji Pharma, Mayne, Merck, Searchlight, and TherapeuticsMD, and is a consultant for Estetra SRL, Libbs, Mayne, and Medicines360. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding for Dr. Creinin from Chemo Research SL, Evofem, HRA Pharma, Medicines360, Merck, and Sebela. Courtney Baker did not report any potential conflicts of interest.

References

    1. Jensen JT, Creinin MD. Contraception, population, and the environment. In: Jensen JT, Creinin MD, editors. Speroff and Darney's Clinical Guide to Contraception. 6th ed. Wolters Kluwer; 2019.
    1. Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep 2020;1:83–93. doi: 10.1016/j.xfre.2020.06.006 - DOI
    1. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 2016;374:843–52. doi: 10.1056/NEJMsa1506575 - DOI
    1. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014;57:635–43. doi: 10.1097/GRF.0000000000000070 - DOI
    1. Ricketts S, Klingler G, Schwalberg R. Game change in Colorado: widespread use of long-acting reversible contraceptives and rapid decline in births among young, low-income women. Perspect Sex Reprod Health 2014;46:125–32. doi: 10.1363/46e1714 - DOI